



May 17, 2025, Monthly Update

Introduction: Wow what a month! A lot is happening.

1. **3-year anniversary of dosing the first Parkinson's disease patients**
2. **Wheelchair to walking: Videos of two Parkinson's disease patients going from a wheelchair, unable to move, to walking again (FGF-1)**
3. **Zhittya awareness efforts: Dan Montano interviewed on the Wayne Allyn Root Show-Top 10 that aired Saturday, May 10.**
4. **Zhittya's New Biomanufacturing lab in Reno, Nevada**
5. **Major changes at the FDA will enhance quicker approvals for Zhittya's medicines.**
6. **Zhittya's launches two Medical Research Studies in the US for: (1) Reversing type-2 diabetes and (2) Neuropathy**
7. **Long-Covid is killing people and destroying their minds, affecting 8% of all Americans and Zhittya may have the only treatment**

(FGF-1)!

- 8. If you are one of our investors, and you want an Update on the status of everything: Email me a day and time to call you. I will brief you and you will be happy! Email: Dan333@aol.com**

#1) Zhittya's 3-year anniversary treating Parkinson's disease patients.

In May 2022, Zhittya dosed the first two Parkinson's disease patients in the British Virgin Islands with FGF-1. May 2025 marks three years since the start of medical experiments on what is now over 200 Parkinson's disease patients. We have seen no adverse events; we have continued to increase the amount of FGF-1 we dose patients and for longer periods of time. In our minds, higher dosing and longer dosing are showing to be beneficial to Parkinson's disease patients. Originally, we dosed at level 1, and now we are at level 17, and I believe in a few months we may raise it again.

We thank our over 200 volunteers who have joined us on this journey of discovery of reversing Parkinson's disease and other neurological diseases. Now that we have a functional MRI scan showing enhanced blood flow in the brain resulting from FGF-1 dosing, now I personally have no doubts we have a treatment which can reverse Parkinson's disease, stroke disabilities, dementia, Alzheimer's disease, autism, and more. I believe more blood flow in the brain makes for better brains!

Recent reports from the new FDA management indicate that the FDA may no longer require duplicate animal testing if existing animal data and/or human safety data already exist. Should the FDA do this, it would be an answer to my

prayers. Conceptually, it means that the 200 people we have already dosed for Parkinson's Disease (and have shown that FGF-1 is safe in the brain), may allow us to apply early next year for a Phase II clinical trial on our treatment for Parkinson's disease. Since Parkinson's disease is an **"Unmet Medical Need"**, we might qualify for the FDA's "Breakthrough Designation", which allows for FDA approval based on Phase II data outcomes. This is a long shot, however, in my mind, we might be able to have our treatment for Parkinson's disease approved now within three to four years by the FDA. Before these recent changes by the FDA, I feared it would take us another 7 to 9 years to get approval. The safety data from our 200 Parkinson's disease patients may have trimmed 3 years off the FDA approval timeline. This is Great News!

#2) Wheelchair to walking

The greatest joy for me over the last three years has been seeing the improvement in Parkinson's disease sufferers we have treated. People who, 3 years ago, had no hope that their life would be anything but a declining living hell, are now improving and having a better life. Two of our test subjects were in wheelchairs. One man, Mark, could not lift his foot because his condition was so bad. You should see the joy we feel at Zhitty when someone confined to a wheelchair is now up and walking. This is our real reward; our patients are getting better.

Below are links to patient videos:

Video Gail: https://www.youtube.com/watch?v=f_DuORdwdkQ

Gail's video on YouTube has 5,400 views, and 98,000 views on X.

Video Mark: <https://www.youtube.com/watch?v=MMhzC9zMe2o>

Mark's video on YouTube has 300 views and 20,000 views on X.

The first video of Mark was on May 17, 2023 (two years ago), now he's up and walking. Gail had started dosing around 18 months ago, and she is getting better and stronger every month. You are witnessing that Parkinson's disease **is NOT an irreversible disease**: here are two warriors coming back to a decent life! We have 200 Parkinson's disease patients improving. We all owe a debt of gratitude to these 200-plus heroes, leading the way to save millions of other people!

#3) Interview on the Wayne Allyn Root Show-Top Ten, which is watched by 1 million people.

On Saturday, May 10, 2025, the Wayne Allyn Root show "Top 10" aired an interview with Dan Montano on Zhittya's medicine to treat heart disease, stroke recovery, Parkinson's disease reversal, reversing type-2 diabetes, treating neuropathy, and more. While having Wayne's 1 million viewers become aware of what Zhittya's medicines means to their health and to the life of millions of people, is great: what is more importantly is the personal relationship that Wayne Allyn Root has with:

the head of Health and Human Services (HHS), Robert F. Kennedy Jr.,
the head of the Centers for Medicare and Medicaid Services, Dr. Mehmet Oz, and
most importantly his close personal relationship with:
the President of the United States, Donald J. Trump.

There is now a passion in Washington, D.C., to get things done using "Common Sense" and to remove the bureaucratic barriers that only harm people.

It is important that people learn that Zhittya Genesis Medicine has shown it can treat small vessel heart disease, the #1 cause of death in the world. Zhittya believes it has a medicine that is reversing Parkinson's disease in humans, enhancing recovery from strokes, and more. I also believe that our medicine to treat these diseases will be at 25% of the present cost of existing treatments. Of the ten people we have dosed intranasally with FGF-1 who were type-2 diabetics, all recovered from that disease. Which is better? 6 days of dosing with Zhittya's medicine to eliminate type-2 diabetes, or 20 years managing the corrosion of type-2 diabetes in a body where health worsens?

If you want to watch the segment of the show, go to:

<https://youtu.be/QzZGLg3ox8Q>

We have had over 4,000 responses in just the first 5 days.

#4) Zhittya's Bio-manufacturing Lab in Reno, Nevada

Biomanufacturing of human molecules using recombinant DNA technology is no easy task. In our human heart clinical studies, one round of dosing with our FGF-1 molecule grew new blood vessels and treated our no-option heart patients and extended their lives. With diabetic foot ulcers, continuous dosing (once every two days) healed non-healing wounds. In the brain, we completely miscalculated what we thought was right 3 years ago. We thought that one round of dosing with FGF-1 would be sufficient. Now we are dosing 17 times higher and for up to 3 years of dosing, and we have seen better improvements. The question now is, can we make more improvements faster with higher dosing?

Over the last 27 years, Dr. Jacobs has overseen the bio-manufacturing of FGF-1 for us. From my calculations of all the FGF-1 ever manufactured, Merck made

about 7% (before they stopped in 1997). Dr. Jacobs has made around 92% and the rest of the world at 1%. The brain seems to absorb FGF-1 like the Nevada desert sucks up a bucket of water tossed on the ground. We are still guessing where it all goes, but what we do see is a dramatic improvement in brain function, which is what really matters.

Here is a picture of Dr. Jacobs with our two research scientists, Tezo & Megan.



It is my opinion that Zhittya now has the capacity to manufacture, in one year, an amount of FGF-1 to equal all that has ever been bio-manufactured before. That is the good news; however, given all we have going on, I fear we will still have to ration out FGF-1 for the next several years, since the demand for FGF-1 seems unlimited.

#5) FDA is relaxing animal data requirements and accepting existing safety data.

Martin A. Makary, M.D., M.P.H. was appointed the head of the US FDA on April 1, 2025. The discussions he is introducing are ideas that are better than my most optimistic prayers. Common sense solutions to get it done could reduce the cost and the time to get a medicine approved in the United States by billions of dollars and by many years. This new attitude at the FDA has caused us to completely change our thinking about how to proceed in getting our medicines to sick people. Taking what is being said by FDA executives is tremendous, although those of us who have worked through bureaucracies before know what the politicians give you in words, the bureaucrats take away in reality. Dr. Makary has stated that delays cost lives and make people suffer so that the FDA will accelerate clearances. Finally, someone at the FDA is on the patient's side! Zhittya has to push forward now to advance our medicine quicker so everyone can be treated.

#6) Zhittya's Medical Research Studies for:

1. Reversing Type-2

2. Diabetes Neuropathy

Zhittya has launched two new Medical Research Studies, which will be conducted at a medical clinic in Las Vegas, Nevada. These studies are being funded by some of Zhittya's investors. We have chosen type-2 diabetes and neuropathy as our first medical studies for two reasons:

Reason One: Shortness of dosing time. In the British Virgin Islands, we have already dosed ten (10) type-2 diabetes patients who all experienced 100% reversal of their diabetes disease with just 6 days of dosing. Treating neuropathy has been like treating heart patients: one round of dosing and done. Therefore,

the Medical Research Studies will be very short at 6 months in length. If we dose people in June 2025, we should have safety data and medical outcome data by January 2026. These are very fast results by biotech standards.

Reason Two: The medical need for both conditions is massive. In the United States and Canada, there are an estimated 40 million people with type-2 diabetes. If, as I believe, we confirm that FGF-1 can reverse type-2 diabetes (effectively curing it), then I believe treating millions of Americans is a tens of billions-dollar business opportunity that could be approved by the US FDA within 3 to 4 years. Neuropathy is estimated to affect 25 to 30 million people in the US and Canada. If FGF-1 can treat that disease that has no current treatment options, we should again have another huge win in a few years.

Funding of Medical Research Studies. Zhittya has many projects, including treating Parkinson's disease, stroke, heart disease, and more. The new biomanufacturing lab and other projects all take money to advance. I have all those costs budgeted, and the funds set aside to complete them over the next 12 months. I can wait the 12 months until I have the extra cash available early in 2026 to start the type-2 diabetes and neuropathy Medical Research Studies, or I can specially fund those Medical Research Studies now with our investors and have that data in 9 months. If I specifically fund these Medical Research Studies now, I believe that in a year from now, we will show that intranasal FGF-1 can reverse type-2 diabetes, which, I believe, is the **"BIGGEST UNMET MEDICAL NEED"** in the world, affecting over 480 million people. I believe Zhittya's cost to treat type-2 diabetes would be around 1/4th the present cost of treating the symptoms of this disease. We have better healthcare for less money. Everybody, except Big Pharma, should be happy. Zhittya has many, many projects we are

trying to advance, and a limiting factor is always the extra money for those new, important projects.

I have been blessed in my 55 years of doing business worldwide as a former California Investment Banker that I have many wealthy friends. Additionally, some of our Parkinson's disease patients believe in what we are doing, as they personally feel the improvements in their lives from FGF-1 being introduced into their brains, they believe it works. A discussion with some of them has led to them funding the first **"Medical Research Study to Reverse Type-2 diabetes."**

When I was an Investment Banker from 1968 until 1998 (30 years) I developed relationships with many wealthy people. I learned the secret to having wealthy people like you is to make them money! During my 30 years as an Investment Banker, I made a lot of money for people. By them funding the Medical Research Studies, besides them being able to know that they helped cure type-2 diabetes, Zhittya is giving them a 5% royalty on Zhittya's future sales of the medicine. The royalties will continue until they have received ten times their original funding.

Some of them have said the 10 times profit sharing was not necessary because it is a wonderful task project they want to be involved in; however, no one has turned down the 10 times return on their investment. That is no surprise to me!

Given this new way for Zhittya to fund these Medical Research Studies quickly and with a high probability of success, we will be looking into doing the same with neuropathy, peripheral artery disease, critical leg ischemia, diabetic foot ulcers, no-option heart disease, and more with short dosing time periods.

Moreover, for our patients, many of whom have been waiting for years for the start of our US-based studies, this allows for our initial patients in these medical research studies to participate without any huge financial barriers. With the

investor sponsors that we have received and are continuing to get a lot of attention with, we can offer these initial studies to more patients.

I would like to have human clinical data by early 2026 to try and go to the FDA for Phase II clinical trials for type-2 diabetes, neuropathy, peripheral artery disease, critical leg ischemia, diabetic foot ulcers, no-option heart patients, and more. I hope to seek FDA approvals in 2027/28. I am personally handling the Special Funding of Medical Research Studies. If you would like more information, please email me at Dan333@aol.com or call me at +1 702-802-8373.

If you wish to be considered for one of the Medical Research Studies, right now, we are recruiting type-2 diabetes volunteers. Again, to gain an understanding, I am handling this myself, and please contact me at Dan333@aol.com. The first type-2 Medical Research Study is for ten people, and we had five volunteers in the first week before we even started recruiting. Out of the 38 million Americans with type-2 diabetes, there are many willing to cure it!

#7) Long COVID is killing and destroying lives:

Many people have been asking us for years if our medicine could do anything about "Long COVID." I haven't replied until now because we do not know what causes it, and our list of important medical tasks is crowded and full right now, so I cannot even look at another task, like Long COVID.

However, on April 15, 2025, *The Wall Street Journal* published a story entitled "Is COVID Rewriting the Rules of Aging? Brain Decline Alarms Doctors."

This article ruined my day. Ugly, Ugly story! Long COVID might affect 40 to 50 million Americans. It seems that the millions of deaths from the COVID-19 pandemic may be the lesser of two evils, as Long COVID is now killing and will

continue to kill many people for a long time. Long COVID may kill a lot more of us than the original COVID-19 pandemic. In August 2021, I was in an ICU (Intensive Care Unit) on a ventilator for ten days, fighting for my life with COVID-19. I survived COVID-19, and I thought that battle was behind me. According to the story, you could lose your mind, have more strokes, and have more heart attacks. Here is the link to our website covering *The Wall Street Journal* story. Read it, if you had COVID-19, **it will ruin your day**:

<https://www.zgm.care/covid>

I thought I had survived and COVID was behind me. Based on *The Wall Street Journal*, "Long COVID" is still coming for me.

After reading that ugly story, I started researching Long COVID, since it now seemed more important to me. For the next two days, for 14 hours a day, I researched this monster coming after me. Wow, wow did I learn a lot.

I have searched and found a lot of data:

1) Dr. Swartz (Canada) title: "Your vascular system and COVID"

<https://www.heartandstroke.ca/articles/a-quick-guide-to-your-vascular-system>.

2) National Library of Medicine. A 42-page article with some great pictures-

"Pathophysiological Mechanism that drive COVID-19 related vascular diseases"—

The Cause of Long COVID: Endothelial Dysfunction. Link:

<https://pmc.ncbi.nlm.nih.gov/articles/PMC10332421/>

3) British Heart Association: "How does Covid-19 affect your heart?"

Again: The cause of Long COVID: endothelial dysfunction.

Link: <https://www.bhf.org.uk/information-support/heart-matters-magazine/news/coronavirus-and-your-health/what-does-coronavirus-do-to-your-body>

Long COVID, according to all these experts, is when the endothelial cells that line your blood vessels are being assaulted by the COVID that is still in the body. This assault leads to those endothelial cells becoming dysfunctional, leading to more heart attacks, strokes, memory loss, etc. More news as we progress, I personally want a treatment for Long COVID now!

#8) Our investors

Many people have invested in Zhittya's Marketing partners. I believe 2025/26 will be a wonderful year for those people. If you are one of our investors, and you would like a confidential briefing from me personally, email me at:

dan333@aol.com and tell me when is a good time to call you. I have great news for you.

Zhittya's Outreach Program

In our March 17, 2025, Update, I introduced our Zhittya Outreach Program, which received strong interest. We have been busy, so advancing our Outreach Program has been slower than I would like. I will get to it soon.

Vika Montano's Patients' Comments Section: Every month, I receive emails and phone calls from our test subjects. Here I have selected a few of their comments

so you can read what those who have joined our Medical Research Studies are reporting to us.

#1) Carol

Hello Zhitty Family!

Please forgive my delay in connecting, but please know this: **You have been in our thoughts everyday** and I'd like to share this update even though it has only been 7.5 weeks since Brad's initial dosing on January 21st.

Daily protocol:

- Brad developed an app customized with his unique PD symptoms
- Every day he tracks the status of each symptom versus the prior day (same, better, worse...)
- He also notes the weather, what he ate, and other environmental impacts including level of stress
- It's too early to analyze the data, but for now he is just building his 'baseline'

Dosing:

- Brad will soon complete his second 3-week 'resetting' period (he doses again on March 18th for 3 days)
- The dosing has been easy, and Brad can self-dose (Special thanks to Vika and Sergiy's careful guidance and oversight on instructing us!)

Meds:

- Brad is ready to reduce his dosage of Rytary carbidopa and levodopa
- He feels like the 61.25 mg capsules are too strong, so we have ordered 48.75 mg capsules
- There are two even smaller doses (36.25 mg and 23.75 mg) – so he can

gradually step down further as his body allows.

Some BIG first steps:

- Brad's moods are more consistent in a good way.
- I can't recall anymore 'freezing' where he cannot move his limbs, in fact, he's been active around the house with gardening and other hobbies.
- Brad had been under pressure at work for the past month to develop a new software app. He was challenged at every stage, and it drained him from the focus he had to put into problem solving. Brad worked long days and even longer nights, and I honestly don't know how he found the focus and concentration – but he did. And finally, this past Friday, Brad's breakthrough finally came and I couldn't be prouder of the new software he developed. I can tell that Brad has renewed confidence that his career as a computer engineer is not over yet!

In summary, I honestly do not believe Brad could have worked at the pace he did this past month before he started the FGF-1 dosing. We find ourselves 'counting the days' until the 3 weeks are up and Brad can dose again. Our spirits are lifted, and we are optimistic and anxious to fast-forward 6 months!

My heart goes out to all of you for making this possible for Brad, and I cannot wait to see you in April for Dr. Jack's tribute dinner.

Grateful and thankful, Carol xxx

#2) Hi Vika,

Just want to share good news. Today, I had my 6-month checkup with my neurologist. There was a drastic improvement in rigidity. None on the right side and very little in the left. I am so excited and grateful.

Sheri XXXXXXXX

Border Medical Tourism

Cross Border Medical Tourism services are for those people who want to be considered for Zhittya's future clinical trials or its current Medical Research Studies. Cross Border's focus is to fill all available slots in the Medical Research Studies in the British Virgin Islands and The Bahamas, while we wait for other clinics to come online.

Cross Border is working on filling the available slots for the next BVI Medical Research Studies (intranasal FGF-1 for Parkinson's disease) on the following dates:

Cohort #37: June 2, 2025 – June 7, 2025

Cohort #38: July 7, 2025 – July 12, 2025

Cohort #39: August 11, 2025- August 19, 2025

I am showing cohorts further out in time since we are filling up faster and have fewer spots open each month.

Please get in touch with Sam Cross at Cross Border Medical if you wish to be considered for the BVI cohorts or slots in The Bahamas. Sam's email address is: sam.crossbordermedical@gmail.com.

In addition, if you are interested in participating in the brain scan studies which will take place at Washington University in St. Louis, please let Sam know. There are a finite number of slots for the imaging studies. These studies will look at brain blood flow before and after treatment with FGF-1.

Upcoming Events

Freedom Fest 2025:

June 11 – 14 in Palm Springs, California

Dr. Jacobs and I will both be presenting at the FreedomFest in June, which normally attracts many elected government officials. Last year, over 2,500 attendees were present. At the 2024 Freedom Fest, Robert Kennedy Jr. was the Keynote Speaker, and we were able to chat with him there.

In his section, Dr. Jacobs will discuss the concept of “endothelial cell dysfunction” and its role in initiating neurodegenerative diseases. He will also discuss the potential role of FGF-1 in reversing this dysfunction.

I will be speaking on the Main Stage about our medical success with Parkinson’s Disease and changing the Federal “Right to Try Law”. Also, I will talk about how we are trying to get Nevada to spring forward on advancing medical innovation within the “States Rights.” I will be discussing how reasonable actions could accelerate medical innovation and lower the barrier to entrepreneurial medical innovators who do not have access to a billion dollars and a willingness to wait 18 years. I have seen amazing medical discoveries over the last 20 years that have not advanced because of the huge barrier of 1 to 2 billion dollars needed to try. Most of the medicines Big Pharma sells you today were developed 40 to 50 years ago. Imagine that without innovative competition, we would not have cell phones or smartphones today. The freedom to compete has made America great and its citizens prosperous!

Nevada legalized gambling in 1931 and turned its barren desert land into an economic miracle. I believe if Nevada legalizes people's right to try a medical

innovation, to save their life or that of someone they love, it is their right. My life and health did not come to me from the government; **these rights to my life and health came from God!**

Germany: May 26, 27 & 28

Zhittya has many friends, investors, and patients from Germany and Switzerland. Recent events have stimulated a wonderful response from this great people. To advance their interest, Sergiy Montano, our VP of Marketing will be making presentations in Germany May 26 through 29.

Monday, May 26, Stuttgart, Germany

Sergiy will be giving an afternoon presentation at his Hotel, the Maritim. If you wish to attend, please contact him.

Tuesday, May 27, Frankfurt, Germany

Sergiy will be giving a luncheon presentation for our existing shareholders and new friends.

Wednesday, May 28 Bielefelder, North Rhine-Westphalia, Germany

Sergiy will brief our investors, patients, and other people on our medical progress and explain our Medical Research Studies to them.

If you wish to attend a presentation or meet with Sergiy in Germany, please email Sergiy: sergiy@zhittyamedicine.com or message him at +1 702-758-9866

Las Vegas, Nevada: June 26, 2025

I will be presenting at the Spring Mountain Republican Women's Club in Las Vegas, NV. The event will be a luncheon at the Suncoast Hotel at 11:30 AM and all

are welcome to attend, especially if you live in Southern Nevada! Email me if you wish more information: dan333@aol.com

Las Vegas: Money Show, July 15 to 17

Dr. Jacobs and I will be presenting at the Las Vegas Money Show Workshop on the topic of:


Parkinson's Disease, Heart Disease, Stroke Disabilities, Type-2 Diabetes all reversed: Medical Breakthroughs with FGF-1 are Happening Now!

The workshop will be on Tuesday, July 15th at 11:00 am – 11:45 am.

Dr. Jack Jacobs

In last month's April Update, I discussed the growing body of evidence that vascular or blood flow issues may be an initiating event in many neurodegenerative brain disorders. It was discussed that this lack of blood flow is caused by a defect in the vascular system where blood vessels become dysfunctional, a disorder referred to as "**endothelial cell dysfunction**".

As shown in the figure below, Zhittya's FGF-1 can heal "endothelial dysfunction" and this has major implications for treating long Covid.



Day 10

Day 15

Day 20

Day 25

Day 30

FGF-1 Treatment 

As stated in last month's Update, Dan and I have started taking FGF-1 to try to postpone the possibility of long COVID endothelial cell destruction to ourselves. Preliminary reports have shown that at least 65 million individuals are estimated to suffer from long COVID-19, with cases increasing daily. There are many symptoms of long COVID-19 and this long list includes fatigue/malaise, joint pain, muscle pain, cough, sputum, shortness of breath, chest pain, hair loss, memory impairment, decreased concentration, headache, depression, olfactory dysfunction, taste disturbance, palpitations, diarrhea, abdominal pain, sleep disturbances, and muscle weakness. The causes of long COVID-19 are largely unknown, but it is thought that disorders in blood vessels undergoing vascular endothelial dysfunction may be a strong candidate for the cause of long COVID-19.

There is growing evidence that long Covid could be linked to lasting damage to the endothelium lining the blood vessels. One study found that people with long Covid symptoms - especially people with fatigue, chest pain and cognitive symptoms - were more likely to have impaired endothelial function. The study demonstrated that dysfunction of the endothelium can persist for at least several months after 'recovery' from Covid-19. Further research is needed to better understand whether this persistent endothelial dysfunction is directly linked to lasting symptoms of Covid-19, but this also raises the possibility that existing treatments which can improve endothelial function (such as FGF-1) could be used to help people who develop long Covid.

Conclusion by Dan Montano

This Update is very full, as we are advancing on many tasks at the same time. Zhittya has many wonderful projects working to advance what, I believe, is the

biggest medical breakthrough of the last 100 years. It is reported that 65% of all adults will die from a disease that is caused by the lack of blood flow to a tissue or an organ. I believe FGF-1, with its ability to trigger new blood vessel growth, could defer death and suffering for 90% of those people. Zhittya has advanced below the radar for decades. I believe over the next 6 months, Zhittya must go out into the public to inform them of what we are accomplishing on many important medical treatments. We have great data; however, the barrier is to get our medicine to the patients, the general public who are sick and need our medicine. Our barrier **is the USA FDA**. I do not want to be deferred another ten years waiting for the FDA to respond to an effective cure for type-2 diabetes, because of all the money they get from Big Pharma to keep selling drugs to deal with the symptoms of diabetes instead of effectively curing type-2 diabetes. Big Pharma drugs are known for dealing with the symptoms of disease; not the cause of the disease. I believe we have a “Window of Opportunity” to advance our medicines and get some approved sooner now that Washington, D.C., is demanding “Common Sense” regulations. I believe our window of opportunity is **44 months**. We must make progress now when we have the wind to our back. Zhittya has been quietly advancing and obtaining great human data. Now we must “Charge into this battle and seek victory, millions of people are in need of our medicine and time delays are not their friend!”

This FGF-1 molecule was discovered over 40 years ago. We and others have used it in medical research and proven it safe with amazing outcomes. From deferring death from heart disease, to treating brain disorders, to reversing diabetes, to neuropathy, and more, yet it has not reached the hundreds of millions of people who could have benefited from it had it been approved in the 1990s. Of the 17

million people who die of heart disease every year, I believe FGF-1 could have prevented (deferred) the deaths of 85% of those people. Using simple math, I will guess 14 million people per year could have been saved if FGF-1 had been approved in 1998. Today, 2025, it is 27 years later, and at 14 million people times 27 years, it is 378 million people whose lives we could have extended, if not for the crazy rules of the FDA to protect those people from what, Life? Those people died because this medicine was trapped in a Byzantine Bureaucracy of delay, delay, delay. Based on that math, FDA delays have been responsible for countless human deaths — not allowing people to heal themselves is wrong!

We have **44 months** to accomplish what has not been accomplished in 46 years, getting FGF-1 to sick humans.

We must rally together and get the FDA to use common sense - making sick people suffer and die is not right. If we cannot get the Federal Government to care about its people's health and life, we will try and get permission in Nevada to do it.

If you have an interest in learning about the “Special Funding of the Medical Research Studies project”, contact me directly at dan333@aol.com or call me at 702-802-8373. Every Special Medical Research Study we can launch in the next 90 days for type-2 diabetes, neuropathy, peripheral artery disease, critical leg ischemia, chronic diabetic foot ulcers, and more, will help speed up approval. We know that millions of people are suffering from these diseases, and many are dying. If it takes Zhittya another 12 months to self-generate the extra cash to fund these projects, I will not suffer, since I have none of these diseases. For the tens of millions of people suffering with these diseases now, I do not want them to suffer and die because I did not try. It is reported in the United States that 120,000

people have had their foot amputated every year because of insufficient blood flow to their lower extremities, which I believe FGF-1 can treat. My wonderful Aunt died from this; it was cruel to watch her being slowly carved away by the doctors; toes, then feet, then legs and then death. I want to get these Medical Research Projects moving, since we have data that shows we should be able to treat these diseases. I will wait no longer to save these people's lives. **When God gives you a purpose-DO IT!**

I pray we all succeed! Bless you all!

Dan Montano, CEO

Zhittya Genesis Medicine

8683 W. Sahara Ave Suite 280

Las Vegas, NV 89117

USA

zgm.care